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Abstract
Objective: With an increasing incidence of Alzheimer’s disease (AD) and neu-
rodegenerative tauopathies, there is an urgent need to develop reliable biomark-
ers for the diagnosis and monitoring of the disease, such as the recently
discovered toxic tau oligomers. Here, we aimed to demonstrate the presence of
tau oligomers in the cerebrospinal fluid (CSF) of patients with cognitive
deficits, and to determine whether tau oligomers could serve as a potential
biomarker for AD. Methods: A multicentric collaborative study involving a
double-blinded analysis with a total of 98 subjects with moderate to severe AD
(N = 41), mild AD (N = 31), and nondemented control subjects (N = 26), and
two pilot studies of 33 total patients with AD (N = 19) and control (N = 14)
subjects were performed. We carried out biochemical assays to measure oligo-
meric tau from CSF of these patients with various degrees of cognitive impair-
ment as well as cognitively normal controls. Results: Using a highly
reproducible indirect ELISA method, we found elevated levels of tau oligomers
in AD patients compared to age-matched controls. Western blot analysis con-
firmed the presence of oligomeric forms of tau in CSF. In addition, the ratio of
oligomeric to total tau increased in the order: moderate to severe AD, mild
AD, and controls. Conclusion: These assays are suitable for the analysis of
human CSF samples. These results here suggest that CSF tau oligomer measure-
ments could be optimized and added to the panel of CSF biomarkers for the
accurate and early detection of AD.
Introduction
Alzheimer’s disease (AD), the most common cause of
dementia in the elderly, imposes a tremendous socioeco-
nomic burden worldwide.1 Increasing life span has aug-
mented the incidence of AD in developed countries, where
the patients are principally at risk of developing this disease
with their increasing age. AD, like other neurodegenerative
disorders, is caused by the abnormal accumulation of
pathogenic protein aggregates. The well-established patho-
logical hallmarks of AD include plaques, consisting mainly
of amyloid-b (Ab) peptides, and neurofibrillary tangles,
consisting of phosphorylated tau (p-tau) protein.2 Prior to
the manifestation of symptoms and clinical diagnosis, the
neurodegenerative processes have already progressed to a
relatively advanced stage with marked synaptic loss and
neuronal damage.3 A recent study by Rajan et al. has shown
that impairment in cognition starts almost 18 years before
AD dementia could be clinically diagnosed.4 The distinc-
tion between memory decline due to the normal course of
aging and early stage AD dementia is so ambiguous that the
category of mild cognitive impairment (MCI) has been
developed to better characterize the earliest signs of AD.5
The MCI category was initially created to identify the early
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stages of AD and was primarily based on impairment in
memory, but with the advances in research made over time,
it was noticeable that some patients with MCI remain stable
while others progress to AD.6,7 Identifying biomarkers at
the preclinical stage of AD is essential in properly diagnos-
ing and determining the probability of developing AD. At
this point, cerebrospinal fluid (CSF) biomarkers are of
great significance, as they reflect the neuropathology of the
diseased brain.8
In 2011, the 1984 diagnostic criteria for AD were revised
by a work group from the National Institute on Aging and
the Alzheimer’s Association. In this modified version, imag-
ing and CSF biomarkers have been integrated into the crite-
ria for pathophysiological processes occurring in AD
dementia.9 Ab42, total-tau (t-tau), and phosphorylated tau
(p-tau) are now considered the major CSF biomarkers in
AD pathogenesis, and they have been included as research
criteria for the diagnosis of AD since 2007.10 Apart from
these core CSF biomarkers, neurofilament light protein
(NFL) and plasma t-tau have also been reported to be asso-
ciated with AD.11 CSF surrounds the brain, acting as a pro-
tective cushion for the brain and spine, and is in direct
contact with the interstitial fluid of the brain. Thus, study-
ing CSF protein profiles may increase the understanding of
the pathological changes occurring in the brain. The t-tau
levels are elevated in the CSF of AD and MCI patients as
compared to normal controls.12,13 In contrast, decreased
levels of CSF Ab42, reflecting plaque pathology, have been
repeatedly and consistently reported in AD patients.14,15
Soon after these reports, increased levels of p-tau were
reported in MCI and AD cases compared to healthy con-
trols.16–19 It has been shown that by measuring the three
core CSF AD biomarkers, t-tau, p-tau (threonine 181), and
Ab42, a 96.4% detection sensitivity for autopsy-confirmed
AD can be achieved.20 Routine clinical use in a central labo-
ratory found high sensitivity and specificity for AD in over
5000 CSF samples.21 This CSF signature appears to predict
conversion from MCI to AD, but did not meet the criteria
for correctly diagnosing MCI or predicting preclinical AD
cases.20,22,23 Elevated levels of total and p-tau (Thr 181) were
also found in the CSF of familial Alzheimer disease (FAD)
mutation carriers (presenilin-1 and APP); these levels were
reported as sensitive indicators for presymptomatic AD.24
Despite, the availability of core CSF biomarkers, identifi-
cation of new biomarkers is highly needed to better
understand the molecular mechanism underlying AD
pathogenesis, 25,26 which will aid in AD diagnosis in its
preclinical stage.27 An evolving concept in AD research is
that the intermediate species in the protein aggregation
process, oligomers, are the most noxious entity that causes
neuronal toxicity. We have previously demonstrated ele-
vated levels of tau oligomers in the soluble fraction of
brain homogenates from patients with AD, Parkinson’s
disease (PD), and dementia with Lewy body (DLB), using
two anti-tau oligomer-specific antibodies, T22 (rabbit
polyclonal), and TOMA (mouse monoclonal).28,29 In this
study, we aimed to measure the level of CSF tau oligomers
in moderate to severe AD, mild AD, and nondemented
controls to test the specific hypothesis that the CSF tau oli-
gomer levels are increased in AD compared to controls.
Methods
Pilot studies
CSF samples (AD; N = 19, Co; N = 14) used for indirect
enzyme-linked immunosorbent assay (ELISA) and Wes-
tern blot analyses were obtained from the Institute for
Brain Aging and Dementia (UC Irvine), Prof. John Ring-
man (Mary S. Easton Center for Alzheimer’s Disease
Research, UCLA), Prof. Randall Woltjer (Oregon Health
and Science University), Prof. Douglas Galasko (Shiley-
Marcos Alzheimer’s Disease Research Center, UCSD)
(Table 1). MMSE scores are available for all patients.
CASI scores are available for the presymptomatic patients
(UCLA samples).24 Prior to analyses, CSF samples were
thawed on ice. Unused samples were aliquoted and refro-
zen at 80°C until further analysis.
Subjects included in clinical study
Subjects in the clinical study were recruited from the CSF
samples from the Memory clinic, Skane University Hospi-
tal, Sweden, and included moderate to severe AD
(N = 41), mild AD (N = 31), and nondemented controls
(N = 26). See Table 2 for demographic and biomarker
characteristics of the patients included in the study. The
individuals were assessed by a medical doctor specialized
in dementia disorders and they had undergone brain imag-
ing and routine laboratory testing as well as neurological,
Table 1. Demographics and cerebrospinal fluid characteristics of the subjects from pilot studies.
Diagnosis
No. of patients
Male/Female Age (Years) MMSE Score Total tau (pg/mL)
pThr181-tau
(pg/mL) Ab42 (pg/mL)
Nondemented control 6/8 79.87  5.15 27.33  2.51 401  181 NA NA
AD 7/12 83.85  8.53 13.87  10.56* 852  124 NA NA
Statistical significance of AD and non-demented control was calculated using Mann-Whitney test, *P < 0.05.
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psychiatric, and cognitive examinations. Patients diag-
nosed with AD fulfilled the DSM-IIIR criteria of demen-
tia30 and the criteria of probable AD defined by NINCDS-
ADRDA.31 The nondemented controls experienced subjec-
tive cognitive symptoms at baseline, but thorough clinical
investigation as well as clinical follow-up revealed that they
were not affected by a dementia disorder or a neurological
disease. Lumbar puncture was performed in all cases as
part of routine clinical practice and procedure and analysis
of the CSF followed the Alzheimer’s Association Flow
Chart for CSF biomarkers.32 All individuals have given
informed consent for research before their samples were
stored in a biobank. A passive consent procedure was then
used where consent for retrospective use of banked sam-
ples and basic data were assumed if individuals did not
actively retract permission, as instructed in local press
advertisements. This study procedure was approved by the
local ethics committee at Lund University Sweden.
Preparation of Ab oligomers
One mg of lyophilized Ab42 peptide was dissolved in
1.5 mL of 50% acetonitrile (acetonitrile:water) and
divided into three portions, each containing 500 lL (ap-
proximately 0.3 mg) and relyophilized. Each tube of
0.3 mg peptide was then dissolved in 200 lL hexafluo-
roisopropanol (HFIP) and incubated for 10–20 min at
room temperature. To this solution, 700 lL dd H2O was
added. Tubes were closed with perforated caps allowing
HFIP to evaporate. Tubes were then stirred at 500 RPM,
using a Teflon-coated micro stir bar for 36 h in the fume
hood at room temperature.
Preparation of recombinant tau oligomers
Recombinant full-length human tau protein (tau 441,
2N4R, 45.9 kDa) was expressed in an E. coli system and
subsequently purified from this system as previously
described.33 This recombinant tau was then oligomerized
following our published protocol.34 In brief, tau protein
was treated with 8M urea to obtain monomers. Aliquots
were stored at 20°C. Monomeric tau was then dialyzed
against 1X PBS and the final volume was adjusted by
adding 1X PBS to a final tau concentration of 0.3 mg/
mL. To this, Ab42 oligomers were added as a seed at a
dilution of 1:140 (w/w) and the sample was incubated at
room temperature for 1 h on an orbital shaker. This oli-
gomer preparation was purified by fast protein liquid
chromatography (FPLC) and used to seed another fresh
batch of monomeric tau. This process was continued for
another batch (third time) of oligomer preparations to
exclude any remaining Ab42 oligomer seed. After three
rounds of tau oligomer preparation, the final sample did
not have any Ab42 oligomer (seed) detected by ELISA
since Ab42/tau ratio was estimated to be <1:2470000. This
final tau oligomer preparation was used to generate stan-
dard curves as well as a positive control for all the ELISAs
performed with CSF samples.
Antibodies
Antibodies against oligomeric tau as well as the total used
for Western blot and ELISA are summarized in Table 3.
Measuring tau oligomers from CSF samples
by ELISA
To measure tau oligomers in CSF samples, 12 lL of CSF
sample per well was added with 0.05 mol/L sodium bicar-
bonate (pH 9.6) as a coating buffer in 96-well ELISA
plates (NUNC, Polysorp). Each sample was plated in
duplicates. Plates were incubated overnight at 4°C. Plates
were then washed 1 time with TBST buffer (containing
0.01% Tween 20), followed by blocking for 2 h at room
Table 2. Demographics and cerebrospinal fluid characteristics of the subjects from clinical study.
Diagnosis
No. of
patients
Male/Female Age (Years) MMSE score Total tau (pg/mL) pThr181-tau (pg/mL) Ab42 (pg/mL)
Nondemented
control
10/16 64.24  9.66 28.17  1.63 378.36  198.76 54  17.49 582.8  177.27
Mild AD 7/24 74.35  8.0 6.27  1.5*** 723.43  277.11**** 101.13  37.47**** 418.30  140.76***
Moderate-severe
AD
13/28 76.72  7.14 17.8  4.54**** 847.43  378.49**** 105.36  46.10**** 333.92  100.55****
AD, Alzheimer’s disease; Ab42, amyloid b42 protein; pThr181-tau, tau phosphorylated at threonine 181; NA, not applicable.
Data are presented as meanSD (standard deviation). Statistical significance of mild AD and moderate-severe AD were calculated compared with
nondemented controls using Mann-Whitney test and presented as.
***P < 0.001.
****P < 0.0001.
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temperature with 10% nonfat dry milk prepared in TBST
buffer. After washing one time with TBST, 100 lL of T22
(1:250) diluted in 5% nonfat milk prepared in TBST was
added and allowed to react for 1 h at room temperature.
Plates were then washed three times with TBST buffer.
T22 immunoreactivity was detected, using 100 lL of
HRP-conjugated anti-rabbit IgG (GE Healthcare, Pitts-
burg, Pennsylvania, United States). The secondary anti-
body (diluted 1:3000 in 5% nonfat milk in TBST) was
added, followed by incubation for 1 h at room tempera-
ture. Finally, plates were washed three times with TBST
and incubated with 100 lL of 3,3,5,5-tetramethylbenzi-
dine (TMB-1 component substrate, from Dako) for 1 h
in the dark. The reaction was stopped by adding 100 lL
2mol/L HCl and the plates were read at 450 nm in a
Polar Star Omega plate reader (BMG Labtech, Cary,
North Carolina, United States). We used calibration
curves generated with recombinant tau oligomer. The
concentration of recombinant tau was measured by Bicin-
choninic Acid Assay (BCA method, Pierce) and then used
to generate the calibration curves against T22 and Tau 5
antibodies. The concentrations of total tau and tau oligo-
mers for the samples were obtained from their corre-
sponding calibration curves by performing linear
regression analyses, using GraphPad prism 6. Graphs were
plotted as median and interquartile ranges.
Western blot analysis of CSF samples
CSF samples from 3 AD patients and 2 controls included
in the pilot study were quantified by the BCA method.
These CSF samples were loaded and run in 4–12% bis-tris
SDS-PAGE gels in nonreducing condition so that each
sample contained 35 lg of CSF protein. Proteins were
transferred onto nitrocellulose membranes. Membranes
were first blocked overnight at 4°C in 10% nonfat dry
milk prepared in 1X TBS-T (containing 0.01% Tween 20)
buffer and were then incubated with primary antibodies
T22 (1:250), TOMA (1:100), TTC-35 (1:250), Tau 5
(1:500), Tau 13 (1:1000), Tau 12 (1:1000) and Tau 46
(1:500) diluted in 5% nonfat dry milk solution for 1 h at
room temperature. After washing three times (5 min
each), membranes were probed with their corresponding
secondary antibodies diluted in 5% nonfat dry milk for
1 h at room temperature. Membranes were washed three
times (first washing for 15 min and next two washes for
5 min). Immunoreactivity with T22 and TTC-35 was
detected with HRP-conjugated anti-rabbit IgG (GE
Healthcare) and TOMA, Tau5, Tau 13, Tau 12, and Tau
46 immunoreactivities were detected, using HRP-conju-
gated anti-mouse IgG (GE Healthcare). Human a -albu-
min antibody (1:1000) was used as loading control for
the CSF samples and its signal was detected, using an
HRP-conjugated anti-human IgG (GE Healthcare).
Finally, ECL plus solution (GE Healthcare) was used for
signal detection. Bands from immunoblots were normal-
ized by their corresponding a-albumin signals, and den-
sitometric quantifications were performed, using ImageJ
software, National Institute of Health.
Spike recovery of recombinant tau
oligomers
A mixture of pooled CSF samples from 9 control subjects
was spiked with two different concentrations of recombi-
nant tau oligomers, 600 pg/mL and 1200 pg/mL (pre-
pared as described earlier). The spiked CSF sample and
another aliquot of the same CSF sample mixture without
any spike were then analyzed by ELISA, using T22 anti-
body. Percent recovery of the spike sample was measured
as compared with nonspiked sample.
Statistical analysis
All raw data obtained from ELISA assays and Western
blot quantifications were first analyzed by Excel. Statistical
analyses of these data were performed, using GraphPad
prism 6 software. Bar graphs from densitometric quantifi-
cation for Western blot bands were plotted as median
and interquartile ranges and the percentage of oligomeric
tau out of total tau were expressed as mean  standard
deviation. The nonparametric Mann–Whitney test was
used as a test of significance for the ELISA assays with
CSF samples and results were represented as median with
interquartile range. To compare the ratio of oligomeric
Table 3. Tau antibodies used in this study.
Antibody Epitope Application Species Source
T22 Tau oligomer Western blot,
ELISA
Rabbit Generated
in-house28;
also we made
it available from
Millipore
(#ABN454)
TOMA Tau oligomer Western blot Mouse Generated
in-house43; also
we made it
available from
Millipore
(#MABN819)
Tau 5 210-230 aa Western blot,
ELISA
Mouse Biolegend
Tau 13 20-35 aa Western blot Mouse Covance
Tau 12 9-18 aa Western blot Mouse Biolegend
Tau-46 404-441 aa Western blot Mouse Covance
TTC-35 Aggregated
tau
Western blot Rabbit In-house
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tau to total tau in the CSF between moderate to severe
AD, mild AD, and nondemented control groups, ANOVA
with Dunnet’s multiple comparisons test was used. A cut-
off value of 0.05 was considered significant for statistical
analyses.
Results
Oligomeric tau aggregates in AD-CSF
Western blot analysis of 3 AD and 2 control CSF samples
from the pilot study, using the anti-tau oligomer antibod-
ies T22 and TOMA clearly showed tau oligomers in the
AD samples, while the signals in the controls were not as
intense (Fig. 1A–F). Tau oligomers detected by these anti-
bodies exhibited different orders of aggregation ranging
from 100 kDa in molecular weight and above. The bands
observed at 100–150 kDa molecular weight, immunoblot-
ted with T22 and TOMA, appeared to correspond to
dimers and/or trimers of tau and were elevated with both
the antibodies (P < 0.001). There was no tau detected
below the dimer/trimer bands (Fig.S1A and B). Guzman-
Martinez et al. had demonstrated tau oligomers in the
platelets of AD patients showing bands between 100 and
190 kDa molecular weights, which is in accordance with
our observation.35 Tau aggregates at the dimer or trimer
size range have also been observed in synaptosome-
enriched fraction from AD brains.36 Using T22 and
Figure 1. Detection and biochemical characterization of tau oligomers in AD-CSF. (A, D) Representative Western blots of CSF samples from 3 AD
patients and 2 controls with anti-tau oligomer antibodies, T22 and TOMA. Immunoblotting with T22 and TOMA antibodies clearly showed tau
aggregates in AD compared to controls. Tau aggregates of differing molecular weights were noted, ranging from 100 kDa and above. (B, E)
Densitometric quantifications of higher molecular weight of tau from the Western blots probed with T22 and TOMA antibodies (indicated in
boxes) showed elevated tau oligomers in the AD CSF samples (P = 0.01). (C, F) Densitometric quantifications of dimer/trimer revealed significantly
increased tau oligomers in AD (P = 0.005 and P = 0.008, respectively) (indicated in boxes). Bands were normalized with a-albumin, used as
loading control. Bars represent median with interquartile ranges. A comparatively weaker band of tau oligomers was also noticed in the AD-CSF
samples at 250 kDa molecular weight with both T22 and TOMA antibodies (indicated with star). (G) Probing with Tau5 antibody showed co-
localization of signal from dimer/trimer as well as from highest band observed in the blots. (H, I) Anti-rabbit IgG and anti-mouse IgG secondary
antibodies were used to show the specificity of the antibodies used. AU, arbitrary unit; CSF, cerebrospinal fluid.
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TOMA, a few other bands were noted above 250 kDa in
AD-CSF samples, but were not detected in control sam-
ples. Densitometric quantification of higher molecular
weight bands labeled with T22 and TOMA antibodies (as
indicated in blue box) showed significant increase in the
AD-CSF samples (P < 0.05) (Fig 1B and E). Tau5 anti-
body confirmed the dimer/trimer bands as well as higher
molecular weight bands (Fig 1G). It also detected mono-
meric tau (Fig 2A). Probing with only anti-rabbit and
anti-mouse secondary antibodies did not show any signal
in these CSF samples (Fig 1H and I). Additionally, we
tested these CSF samples with two N-terminal tau anti-
bodies, Tau 13, and Tau 12, C-terminal antibody Tau 46,
and another in-house rabbit polyclonal antibody, TTC-35
that recognizes aggregated tau (Fig 2B–E). Tau 13 anti-
body detected monomeric tau between 60 kDa and
37 kDa molecular weight in both AD and control CSF
samples that were not recognized by the anti-tau oligo-
meric antibodies. Tau 12 antibody also detected monomer
in these samples. Additionally, Tau 46 antibody detected
both high-molecular weight tau and monomeric tau
monomer. TTC-35 antibody reacted with the higher
aggregates of tau which was observed only in the two
AD-CSF samples and also with tau dimer/trimer. A much
weaker signal is observed at 250 kDa molecular weight in
the two AD samples, further verifying the tau oligomers
in these CSF samples. We performed two independent
pilot studies with ELISA, using T22 antibody to confirm
tau oligomers in the CSF samples observed from Western
blot. ELISA results were used to quantify tau oligomers
interpolated from the calibration curve which was gener-
ated against recombinant tau oligomers (Fig 3A and B).
Figure 2. Confirming tau oligomers in CSF from multiple independent studies by biochemical analyses. (A–E) Representative Western blot
showing differing orders of tau oligomers versus monomer in CSF, using Tau 5, tau 13, Tau 12, tau, 46 and a rabbit polyclonal antibody TTC-35.
Immunolabeling with rabbit polyclonal TTC-35 demonstrated the presence of both higher tau aggregates as well as its dimer/trimer (indicated in
boxes). Tau 13 antibody detected both tau dimer/trimer and monomer (indicated in boxes). Tau 46 demonstrated high-molecular weight tau as
well as its monomer. Whereas, Tau 12 antibody explicitly demonstrated monomeric tau. A band was noted in AD-CSF samples at 250 kDa
molecular weight (indicated with star) that was also noticed with T22 and TOMA antibodies.CSF, cerebrospinal fluid.
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Both the studies showed significant presence of tau oligo-
mers in AD-CSF samples in comparison with control CSF
(P = 0.002 and P < 0.0001, respectively).
We quantified the dimer/trimer signal at 100-150 kDa
molecular weight detected by T22, TOMA and Tau 5
antibodies in the Western blot. Intensity values from T22
to Tau 5 signals were compared and percentage of oligo-
meric tau (mostly at dimer/trimer) was measured. Similar
percentage quantification was also performed for oligo-
meric tau (dimer/trimer) detected by TOMA and Tau 5
antibodies (Supplementary Fig 1D and E). Approximately,
35–40% of the total tau detected by Tau 5 antibody was
detected as tau oligomers in AD (P < 0.05 for T22,
P < 0.005 for TOMA). To rule out any matrix interfer-
ence in the CSF sample assay, we spiked the CSF samples
with various concentrations of recombinant tau oligomers
and the spiked CSF samples were assayed by ELISA for
oligomers with around 100% recovery (Fig. S1C).
Finally, we performed a double-blinded clinical study,
including CSF samples from 41 moderate to severe AD,
31 mild AD, and 26 nondemented controls. We measured
tau oligomer levels in these samples, using T22 (Fig 3A).
The total tau concentration was determined, using sand-
wich ELISA (Innotest hTAU-Ag, Innogenetics, Gent,
Figure 3. The ratio of tau oligomers to total tau is decreased in AD. (A, B) CSF samples from two independent pilot studies were analyzed by
ELISA, using T22 antibody. T22-reactive tau oligomers from these ELISA assays were then quantified using a standard curve generated against
recombinant tau oligomers. AD-CSF samples clearly showed significant level of tau oligomers as compared to controls (P = 0.002 and P < 0.0001,
Mann-Whitney test). Data points were represented as median with interquartile ranges. (C) A double blinded analysis of large cohort of CSF
samples from moderate-severe AD (N = 41), mild AD (N = 31) and nondemented controls (N = 26) was performed using T22 antibody in ELISA.
Tau oligomers were quantified from this analysis using a standard curve generated against recombinant tau oligomers. Tau oligomers were
significantly increased in groups of moderate to severe AD and mild AD patients when compared with controls (P < 0.05, Mann–Whitney test).
(D) The ratio of oligomeric tau to total was plotted for all the 3 groups of CSF samples. The oligomeric tau to total tau ratio was significantly
increased in control groups in comparison with mild AD and then moderate to severe AD groups (P < 0.0001 between both the groups). Data
were represented as median with interquartile ranges. One-way ANOVA with Dunnets’s multiple comparisons test was used for statistical
analyses.CSF, cerebrospinal fluid. *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001.
232 ª 2017 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
Cerebrospinal Fluid Tau Oligomers in AD U. Sengupta et al.
Belgium). Increased levels of tau oligomers were observed
in AD samples as compared to the controls (P = 0.01).
The ratios of oligomeric tau to total tau were plotted sep-
arately for each of the three groups of samples, and we
found that the control group had the highest ratio fol-
lowed by mild AD, whereas the moderate to severe AD
group exhibited the lowest value (Fig 3B). The ratio was
significantly lower in both the moderate to severe AD and
mild AD groups than in the control group (P < 0.0001).
Discussion
AD is a devastating disorder that heavily impacts society,
both emotionally and economically. Given the aging pop-
ulation, and the fact that AD is the most common form
of dementia in the elderly, it is expected that the preva-
lence of this grave condition will increase. AD can be
definitively diagnosed only after death by combining clin-
ical assessment and the histopathological analysis of the
autopsied brain. Earlier, AD was only diagnosed once the
clinical symptoms have become sufficiently apparent. This
is problematic, because the destructive process of degener-
ation in the brain begins almost a decade prior to the
appearance of the first symptoms.37 This argues almost
unequivocally for the significance of identifying tools,
techniques or methods to diagnose AD in the preclinical
stage. Although the exact mechanism of neurodegenera-
tion is still not known in detail, the role of tau undergo-
ing posttranslational modification, conformational
changes and aggregation has received much attention in
recent years. The levels of tau in CSF are being used as a
complementary biomarker, and the quantification of both
t-tau and p-tau (threonine 181) have been validated by
frequent testing of human CSF samples in several clinical
studies. Increased concentration of tau was detected
almost 15 years before the onset of symptoms was
expected in the CSF of AD patients.38 A growing number
of studies point to the roles of oligomeric assemblies of
pathogenic proteins in toxicity and propagation of AD.
Here, we present our findings from multiple independent
studies showing that the levels of CSF tau oligomers are
present and are increased in the CSF of AD patients. Tau
aggregations at different molecular weights were noticed
in these patients. Our observation suggests that tau oligo-
mer levels in human CSF have the potential to serve as a
valuable biomarker for AD. We also found increased
levels of tau oligomers in AD samples compared to sam-
ples from mild AD and controls, and in fact the levels
descended in that order. Measurements of both the levels
of tau oligomers and the ratio of oligomeric tau to total
tau, once reproduced across multiple laboratories using
different cohorts, have the potential to serve as an indica-
tor for disease progression.
Although CSF Ab and tau, with their limitation to
standardization and sensitivity, reveal the disease pathol-
ogy to some extent, only a handful of fluid biomarkers
have been identified for AD after extensive research.39 We
have previously demonstrated that tau oligomers also act
as the pathological species in the disease progression of
progressive supranuclear palsy (PSP) patients.40 More-
over, tau oligomers have been identified in cortical and
striatal brain regions in patients with other amyloid dis-
eases, such as Huntington’s disease.41 These observations
further support testing the levels of tau oligomers in the
CSF of other tauopathies as well as other neurodegenera-
tive diseases. Although, our results suggest that CSF tau
oligomers could be used as a potential biomarker in com-
bination with the core biomarkers, additional studies,
especially longitudinal ones, are required. Such studies are
critical not only to diagnose the disease pathology more
accurately, but also to prepare for evaluating the upcom-
ing and exciting anti tau therapeutic approaches which
have been initiated recently in clinical trials.42 Identifying
novel CSF biomarkers for AD may supplement the tradi-
tional neuropsychological and imaging diagnostic
techniques used for early diagnosis, and may become a
useful surrogate for evaluating the pharmacological action
of therapies targeting AD and other tau-associated
dementias.
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